What are the side effects of lamivudine tablets?
Sep 27, 2024
Source: Cainiu Health
Dr. Yang Ziqi
Introduction
Lamivudine tablets are an antiviral medication, generally used to treat adult patients with chronic hepatitis B who have elevated alanine aminotransferase levels, active viral replication, and compensated liver function. Main side effects include allergic reactions, nausea, vomiting, headache, muscle pain, and abnormal liver function. Lamivudine should be used strictly under medical supervision; self-medication without guidance is strongly discouraged.
Lamivudine tablets are an antiviral medication, generally used to treat adult patients with chronic hepatitis B who have elevated alanine aminotransferase levels and active viral replication, but with compensated liver function. Its main side effects include allergic reactions, nausea and vomiting, headache, muscle pain, and liver function abnormalities.
1. Allergic reactions: Some patients may experience allergic reactions to lamivudine tablets, manifesting as rash, urticaria, or skin itching. Individuals with hypersensitive constitutions should use this medication cautiously.
2. Nausea and vomiting: Lamivudine tablets may irritate the gastrointestinal mucosa or alter the microbial environment in the intestines, leading to symptoms of nausea and vomiting.
3. Headache: Lamivudine tablets may affect the central nervous system, causing headaches in some patients.
4. Muscle pain: In a small number of patients, lamivudine tablets may affect body metabolism after administration, resulting in muscle pain.
5. Liver function abnormalities: Lamivudine tablets may adversely affect liver function, potentially leading to increased transaminase levels. Therefore, close monitoring of liver function is necessary during treatment.
Lamivudine tablets should be taken strictly under medical supervision; self-medication without guidance is strongly discouraged. If any adverse symptoms occur, prompt medical consultation is recommended to avoid delays in diagnosis and treatment.
